- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.95 Å
- Oligo State
- hetero-3-3-mer
- Ligands
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.2: 9 residues within 4Å:- Chain C: N.66, E.68, E.88, N.89, C.92, S.139, K.221, R.223
- Ligands: IOD.22
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:R.223, C:R.223
NAG-NAG-BMA-MAN-MAN.4: 11 residues within 4Å:- Chain E: N.66, E.68, E.88, N.89, C.92, S.139, K.221, R.223, G.224
- Ligands: IOD.38, IOD.48
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:R.223, E:K.221, E:G.224
- 7 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.6: 1 residues within 4Å:- Chain A: N.25
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:N.25
NAG.7: 4 residues within 4Å:- Chain A: N.129, T.131, R.132, T.156
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:N.129, A:T.131, A:R.132
NAG.8: 1 residues within 4Å:- Chain A: N.13
No protein-ligand interaction detected (PLIP)NAG.19: 1 residues within 4Å:- Chain C: N.25
1 PLIP interactions:1 interactions with chain C- Hydrogen bonds: C:N.25
NAG.20: 1 residues within 4Å:- Chain C: N.157
No protein-ligand interaction detected (PLIP)NAG.34: 1 residues within 4Å:- Chain E: N.25
1 PLIP interactions:1 interactions with chain E- Hydrogen bonds: E:N.25
NAG.35: 1 residues within 4Å:- Chain E: N.157
1 PLIP interactions:1 interactions with chain E- Hydrogen bonds: E:N.157
- 36 x IOD: IODIDE ION(Non-functional Binders)
IOD.9: 2 residues within 4Å:- Chain A: G.55, C.57
Ligand excluded by PLIPIOD.10: 3 residues within 4Å:- Chain A: E.88, G.90
- Ligands: NAG-NAG.1
Ligand excluded by PLIPIOD.11: 2 residues within 4Å:- Chain A: Y.93, H.182
Ligand excluded by PLIPIOD.12: 2 residues within 4Å:- Chain A: K.191, R.195
Ligand excluded by PLIPIOD.13: 3 residues within 4Å:- Chain A: D.278, T.279, K.280
Ligand excluded by PLIPIOD.14: 3 residues within 4Å:- Chain A: R.321
- Chain B: G.1, L.108
Ligand excluded by PLIPIOD.15: 2 residues within 4Å:- Chain A: D.16, T.17
Ligand excluded by PLIPIOD.16: 4 residues within 4Å:- Chain A: D.19, K.313, R.315
- Chain B: V.100
Ligand excluded by PLIPIOD.17: 2 residues within 4Å:- Chain A: P.94, G.95
Ligand excluded by PLIPIOD.18: 3 residues within 4Å:- Chain B: Q.30, N.145, E.147
Ligand excluded by PLIPIOD.21: 3 residues within 4Å:- Chain C: G.55, C.69, E.70
Ligand excluded by PLIPIOD.22: 3 residues within 4Å:- Chain C: E.88, G.90
- Ligands: NAG-NAG-BMA-MAN-MAN.2
Ligand excluded by PLIPIOD.23: 1 residues within 4Å:- Chain C: N.247
Ligand excluded by PLIPIOD.24: 1 residues within 4Å:- Chain C: L.163
Ligand excluded by PLIPIOD.25: 2 residues within 4Å:- Chain C: Y.93, H.182
Ligand excluded by PLIPIOD.26: 2 residues within 4Å:- Chain C: K.191, R.195
Ligand excluded by PLIPIOD.27: 4 residues within 4Å:- Chain C: D.19, K.313, R.315
- Chain D: V.100
Ligand excluded by PLIPIOD.28: 3 residues within 4Å:- Chain C: T.17, K.313, R.315
Ligand excluded by PLIPIOD.29: 2 residues within 4Å:- Chain C: P.94, G.95
Ligand excluded by PLIPIOD.30: 3 residues within 4Å:- Chain C: N.129, I.130
- Ligands: NAG-NAG.3
Ligand excluded by PLIPIOD.31: 4 residues within 4Å:- Chain C: R.321
- Chain D: G.1, I.6, L.108
Ligand excluded by PLIPIOD.32: 3 residues within 4Å:- Chain D: Q.30, N.145, E.147
Ligand excluded by PLIPIOD.33: 1 residues within 4Å:- Chain E: L.22
Ligand excluded by PLIPIOD.36: 4 residues within 4Å:- Chain E: L.54, G.55, C.57, E.70
Ligand excluded by PLIPIOD.37: 1 residues within 4Å:- Chain E: L.72
Ligand excluded by PLIPIOD.38: 5 residues within 4Å:- Chain E: E.88, G.90, T.91, C.92
- Ligands: NAG-NAG-BMA-MAN-MAN.4
Ligand excluded by PLIPIOD.39: 1 residues within 4Å:- Chain E: N.247
Ligand excluded by PLIPIOD.40: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIPIOD.41: 2 residues within 4Å:- Chain E: Y.93, H.182
Ligand excluded by PLIPIOD.42: 1 residues within 4Å:- Chain E: R.195
Ligand excluded by PLIPIOD.43: 1 residues within 4Å:- Chain E: D.278
Ligand excluded by PLIPIOD.44: 2 residues within 4Å:- Chain E: R.321
- Chain F: L.108
Ligand excluded by PLIPIOD.45: 2 residues within 4Å:- Chain E: D.19, R.315
Ligand excluded by PLIPIOD.46: 3 residues within 4Å:- Chain E: T.17, K.313, R.315
Ligand excluded by PLIPIOD.47: 2 residues within 4Å:- Chain E: P.94, G.95
Ligand excluded by PLIPIOD.48: 2 residues within 4Å:- Ligands: NAG-NAG-BMA-MAN-MAN.4, NAG-NAG-BMA-MAN-MAN.4
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ghafoori, S.M. et al., Structural characterisation of hemagglutinin from seven Influenza A H1N1 strains reveal diversity in the C05 antibody recognition site. Sci Rep (2023)
- Release Date
- 2021-10-06
- Peptides
- Hemagglutinin HA1 chain: ACE
Hemagglutinin HA2 chain: BDF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BC
CE
FB
bD
cF
f
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.95 Å
- Oligo State
- hetero-3-3-mer
- Ligands
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 7 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 36 x IOD: IODIDE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ghafoori, S.M. et al., Structural characterisation of hemagglutinin from seven Influenza A H1N1 strains reveal diversity in the C05 antibody recognition site. Sci Rep (2023)
- Release Date
- 2021-10-06
- Peptides
- Hemagglutinin HA1 chain: ACE
Hemagglutinin HA2 chain: BDF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BC
CE
FB
bD
cF
f